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Summary To evaluate the risk of second primary myeloid leukaemia due to radiotherapy and chemotherapy
administered for a first primary cancer, we conducted a population-based case-control study consisting of 97
cases and 194 controls matched on age, date of diagnosis, and site of initial primary cancer among residents of
13 counties in western Washington State. The risk of myeloid leukaemia in patients who received cyclophos-
phamide as part of their chemotherapy regimen was 7.4 (95% confidence interval 1.3-43.8). This risk was not
altered appreciably by the administration of radiotherapy. Compared to patients not receiving any
chemotherapy, the relative risk among patients who received prednisone in combination with cyclophos-
phamide (odds ratio 44.4 95% confidence interval 4.0-496.2) was nearly four times that among patients
receiving cyclophosphamide without this steroid (odds ratio 12.6 95% confidence interval 2.4-64.9). The
relative risk of second primary myeloid leukaemia in patients who received both prednisone and drugs other
than cyclophosphamide (odds ratio 64.2 95% confidence interval 2.6-1582) was 20 times that among patients
receiving drugs other than cyclophosphamide and no prednisone (odds ratio 3.2 95% confidence interval
0.6-16.9). These risk estimates were higher when the analysis was restricted to acute myeloid leukaemia. There
was no increased risk of second primary myeloid leukaemia associated with radiotherapy. The single unique
finding is that the use of prednisone in chemotherapy regimens may enhance the leukaemogenic effect of other
chemotherapy drugs.
Development of a second cancer in general (Boivin & Hut-
chison, 1981; Valagussa et al., 1986; Pen, 1982; Rosner et al.,
1982; Kushner et al., 1988; Tucker et al., 1988), and
leukaemias in particular (Haas et al., 1987; Curtis et al.,
1984; Einhorn, 1978; Boivin et al., 1986; Portugal et al.,
1979; Rosner et al., 1978; Tucker et al., 1987; Reimer et al.,
1977), following treatment for a first primary cancer is being
increasingly reported. There is some evidence that the risk
associated with treatment is greater for acute nonlymphatic
leukaemia than other types of leukaemias (Van der Velden et
al., 1988; Mehnert et al., 1986; Greene et al., 1983; Greene et
al., 1982; Kaldor et al., 1990a; Kaldor et al., 1990b). In-
creased risks have been reported among patients receiving
radiotherapy for cancer of the cervix, chemotherapy for
cancers of the breast, ovary, non-Hodgkin's lymphoma and
childhood cancer, as well as those receiving radiotherapy and
chemotherapy for Hodgkin's disease (Boivin & Hutchison,
1981; Valagussa et al., 1986; Kushner et al., 1988; Tucker et
al., 1988; Rosner et al., 1978; Tucker et al., 1987; Reimer et
al., 1977; Van der Velden et al., 1988; Mehnert et al., 1986;
Greene et al., 1983; Greene et al., 1982; Kaldor et al., 1990a;
Kaldor et al., 1990b; Boice et al., 1987).
Most prior investigations have been based on cases from
single institutions or clinical trial groups (Van der Velden et
al., 1988; Greene et al., 1983), and have generally included
small numbers of cases. Few population-based (Haas et al.,
1987) investigations have been reported. Although Kaldor et
al. have recently described two large collaborative studies of
leukaemia following chemotherapy (Kaldor et al., 1990a;
Kaldor et al., 1990b) which greatly improve upon previous
such work, collectively these studies have not been capable of
evaluating the independent and joint effects of radiotherapy
and chemotherapy, or of specific chemotherapeutic agents or
doses at which such drugs were administered. Further, none
of the previous studies have examined the haematologic
status of patients at the time of the diagnosis of the initial
primary cancer, so that patients who had pre-leukaemic con-
ditions (and thus probably would have developed leukaemia
regardless of the therapy received) could be excluded from
the analyses.
To address these issues, we undertook a population based
case-control study of myeloid leukaemia as a second primary
cancer following an initial (first) primary cancer of any site.
Methods
Selection of cases
From the Cancer Surveillance System (CSS), a population
based cancer registry operated as part of the Surveillance,
Epidemiology and End Results Program of the National
Cancer Institute, 10,331 patients with a lymphohemopoietic
malignancy (ICD-O Morphology code: 95903-99703) diag-
nosed between 1974 and 1986 among residents of 13 counties
in western Washington state were identified. Of these, 893
patients developed a lymphohemopoietic malignancy subse-
quent to a previous cancer. In this group there were 152
patients with acute nonlymphatic leukaemia (herein the term
acute myeloid leukaemia also refers to these patients) and 50
with chronic myeloid leukaemia (ICD-O 98403-98943 except
98503; 98003-98043). Since the CSS commenced operation
in 1974, those patients in whom the first primary cancer was
diagnosed before 1974 were excluded. In order to facilitate
matching and collection of complete treatment information,
the study was further restricted to residents of the three most
populous counties (King, Pierce and Snohomish) covered by
the CSS, which constituted 82% of the remaining cases.
Thus, 72 patients with acute nonlymphatic leukaemia and 25
patients with chronic myeloid leukaemia were available for
inclusion in the study.
Selection ofcontrols
Four potential controls were identified for each case from the
CSS to allow for the possibility that medical records might
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be unavailable for some controls. Each potential control was
matched to the corresponding case within 5 years of age at
the time of the diagnosis of the first primary cancer, and on
the basis of primary site and year of diagnosis of the first
primary cancer. Potential controls were also required to have
survived at least the same length of time as that between the
corresponding case's diagnosis of first primary cancer and
subsequent leukaemia diagnosis. Two of the four potential
controls for each case were selected at random for inclusion
in the study. Upon investigation, medical records were
unavailable for one or both of the two selected controls for
11 (11%) of the 97 cases. For these cases, the third and
fourth potential controls were included in the study. Controls
were not matched to cases by hospital or by stage of disease
as this may have led to matching on staging policy and
treatment. Although stage of disease is clearly associated
with the choice of treatment for most forms of cancer, there
is no evidence to suggest that stage, independent of treatment
modality, is also associated with the development of
leukaemia subsequent to therapy for a first primary cancer.
Consequently, stage of disease would be unlikely to confound
the association under investigation.
Patient information
Data for this investigation were obtained primarily by
reviewing hospital medical records for each subject. For a
few subjects (eight cases and 13 controls) additional inform-
ation (on dose of chemotherapy) was obtained from files of
patients' physicians. The medical chart review consisted of
identifying and verifying patient's age, sex, race and other
demographic details already obtained through the CSS, fol-
lowed by a detailed abstraction of each patient's medical
history and information relating to the diagnosis and treat-
ment of the initial cancer.
Radiotherapy Details of any radiotherapy given were
obtained from radiotherapy summary sheets, which included
the site of radiation, type of energy used, field size, total
tumour dose, fractions of radiation per day and elapsed days
and dates of commencement and completion ofradiotherapy.
Chemotherapy Information on chemotherapy was first
obtained from the initial plan of treatment. The course(s) of
chemotherpy administered during the patient's stay in the
hospital, as well as that on subsequent admissions or out-
patient treatments, were recorded from progress and/or
nurses' notes. The various types of chemotherapy drugs used
with doses, dates and route of administration were recorded
and wherever available chemotherapy flow chart data (as
noted by nurses administering the drugs) were cross-checked
with information on medical records and physician files.
Follow-up details of chemotherapy (except that on dose in
three cases and one control), including changes in drug
regimen, were complete for all patients. An a priori decision
was made to consider the corticosteroid prednisone as a
chemotherapy drug only when it was given for that purpose,
either alone or in combination with other chemotherapy
drugs.
The chemotherapy drugs that were administered to patients
(cases and controls) in this study were prednisone, BCNU,
cisplatin, cyclophosphamide, doxorubicin (adriamycin), hexa-
methylmelamine, vincristine, VP-16, methotrexate, 5-
fluorouracil, melphalan, CCNU, chlorambucil, vinblastine,
mitomycin-C, ara-C and thiotepa. From the dates recorded
and the days over which each drug was administered, both
the cumulative dose and average daily dose (mgday-1) was
calculated. Of the 62 patients who received chemotherapy,
one case and three controls received only topical applications
and these patients were considered as not having received
chemotherapy for the purpose of the study. Patients who
received chemotherapy were grouped into quartiles or tertiles
of average daily dose (mgday-') based on the distribution of
the respective drug among the controls. Aggregation by cumulative dose was done based upon amount of drug
received during courses of 3, 6, or more than 6 months
duration. It was not possible to classify patients receiving
chemotherapy according to the mechanism of action ofdrugs
(e.g., alkylating vs nonalkylating, cell cycle specific vs not cell
cycle specific) because patients generally received drugs in
combinations.
Treatment information was recorded until the time ofdiag-
nosis of the second cancer (myeloid leukaemia) for case
subjects. For control subjects, such details were obtained for
the same time interval as the corresponding case. All details
of radiotherapy and chemotherapy were recorded as they
appeared in the medical charts of both cases and controls.
Review of medical records with complete follow-up was
possible in 93 of 97 (96%) cases and 181 of 194 (93%)
controls. In the remainder, details were obtained from CSS
abstract forms, which provide basic information on diag-
nosis, initial treatment and follow-up. However, none of
these latter patients in whom details were abstracted from
CSS forms alone had any history of having received radio-
therapy and/or chemotherapy.
The distribution of sites of first primary cancer was as
follows (numbers in parentheses is number of matched sets):
lip (1), parotid gland (1), colon (8), rectum (4), gastrointes-
tinal tract (2), nasal cavity (1), lung (8), malignant lymphoma
(8), connective tissue (1), malignant melanoma (1), breast
(18), cervix (2), endometrium (3), ovary (8), vulva (1), pros-
tate (19), urinary bladder (5), kidney (2), eye (1), brain (2),
and thyroid (1). The first primary cancer was microscopically
confirmed in 98% of the subjects.
Haematological status at diagnosis of the first primary
cancer Because the purpose of this study was to evaluate
the risk of myeloid leukaemia associated with radiotherapy
and chemotherapy for a first primary cancer, it was import-
ant to identify and to be able to exclude from the analysis
subjects with haematologic abnormalities documented at or
prior to the diagnosis of the first primary cancer that might
precede the development of myeloid leukaemia. Therefore,
the complete medical record of the 93 cases and 181 controls
with complete follow-up were reviewed in an identical man-
ner to ascertain information initially recorded at or prior to
the diagnosis of the first primary cancer that would indicate
the presence of a haematologic abnormality prior to therapy
for the first cancer. A total of 17 such subjects were
identified; all cases. Eleven had a haematologic abnormality
diagnosed prior to the diagnosis of the first cancer. These
haematologic changes (granulocytic hyperplasia with shift to
the left of WBC (three cases), polycythemia vera (two cases),
maturation arrest of WBC-preleukaemia (one case),
myelodysplastic syndrome (one case), myeloproliferative
disorder (one case), chronic monocytosis, possibly chronic
myelomonocytic leukaemia (one case), leukopenia and
sideroblastic marrow (one case), and refractory anaemia with
excessive blasts (one case)) are known to precede the
development of myeloid leukaemia (Jacobs, 1987; Koeffier,
1986; Bennett, 1986; Wolf & Neiman, 1988). In four cases
the diagnosis of myeloid leukaemia (chronic myeloid
leukaemia (three cases) and acute myeloid leukaemia (one
case)) was made at the time of diagnosis of the first primary
cancer and in two cases a haematologic abnormality (one
with granulocytic hyperplasia with shift to the left of WBC,
and one with thrombocytopenia, possibly acute myeloid
leukaemia) was ascertained at the diagnosis of the first
primary. Since the leukaemogenic process in these 17 cases
very likely preceded the therapy administered for the initial
primary cancer, our results regarding the role of radiotherapy
and chemotherapy are presented with and without these sub-
jects (and their matched controls). For detailed analysis on
the effect of chemotherapy, the relative risks were calculated
only after excluding this group ofpatients (17 cases and their
matched controls).
Statistical methods
Maximum likelihood estimates of the odds ratio (OR) were
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logistic regression. This procedure accounted for the matched
design of the study and allowed for adjustment for covariates
not included among the matching variables (Breslow & Day,
1980). Ninety-five percent confidence intervals (CI) for the
odds ratios were calculated using the standard error of the
regression estimates and the normal approximation (Breslow
& Day, 1980).
Results
The cases and controls were similar with respect to the
distribution of the matching factors (age, site and year of
diagnosis of first primary cancer). The age of the subjects at
diagnosis ranged from 22 to 96 years, with the mean ages of
cases and controls being 67.5 and 68.6 years, respectively.
Radiotherapy
Administration of radiotherapy for an initial primary cancer
was not associated with an increased risk of myeloid
leukaemia (OR 1.0, 95% CI 0.6-1.9), although it increased
slightly when chronic myeloid leukaemia alone was con-
sidered (OR 1.2, 95% CI 0.3-4.6), and when the group with
prior haematologic abnormalities was excluded (OR 1.2, 95%
CI 0.7-2.3). The risks declined slightly following adjustment
for chemotherapy. Type of radiotherapy, dose administered,
as well as site of radiation did not influence the risk of
myeloid leukaemia.
Chemotherapy
The risk of second primary myeloid leukaemia associated
with any chemotherapy was 7.8 (95% CI 2.6-22.9); among
patients without a prior haematologic abnormality this in-
creased risk was somewhat higher (OR 10.3, 95% CI
3.0-34.9) (Table I). These elevated risks were largely
confined to patients with acute myeloid leukaemia and the
results were essentially unchanged following adjustment for
radiotherapy. There was no evidence that patients who
received both radiotherapy and chemotherapy were at a
higher risk of second primary myeloid leukaemia than those
patients who received chemotherapy alone.
Individual drugs Of the 17 drugs administered to the study
population (see Methods), nine (prednisone, ciplatinum, cyclo-
phosphamide, adriamycin, vincristine, VP-16, methotrexate,
5-fluorouracil and melphalan) were administered to enough
patients to permit analyses of risks associated with specific
drugs. Since these drugs are typically administered in com-
binations, the assessment of risk of myeloid leukaemia
associated with a specific drug has to be, to some extent,
indirect. A number of approaches were employed to deter-
mine which of the drug(s) may be more important in
influencing the development of second primary myeloid
leukaemia.
We began by estimating the relative risks of each drug
specified above in two ways. First, we estimated the risk
associated with a patient having received a particular drug
relative to having not received that drug. Second, we
estimated the risk associated with a patient having received a
drug relative to patients not having received any chemo-
therapy. We then selected for further analyses those drugs for
which the risk of second primary myeloid leukaemia was
significantly elevated in both instances. These drugs were
cyclophosphamide, vincristine, methotrexate, and prednisone.
To assess the independent effect of each of these four
drugs, combinations of two, three, and finally all four drugs
were introduced into a conditional logistic regression model.
The risk of second primary myeloid leukaemia was elevated
only among recipients of cyclophosphamide and/or pred-
nisone (prednisone: OR 10.2, 95% CI 1.1-94.6; cyclophos-
phamide: OR 7.4, 95% CI 1.3-43.8). No elevated risk was
observed for vincristine (OR 0.4, 95% CI 0.03-3.9) or
methotrexate (OR 0.9, 95% CI 0.1-7.9) when either or both
of the other drugs were in the model.
The risk estimates of second myeloid leukaemia associated
with the presence of prednisone or cyclophosphamide in the
chemotherapy protocol are shown in Table II. These
estimates exclude persons with a prior haematologic abnor-
mality. The risk of developing a second myeloid leukaemia
among patients who received prednisone with any chemo-
therapy (OR 44.8, 95% CI 4.5-443.3) was over six times that
of those patients who received chemotherapy without pred-
nisone (OR 7.1, 95% CI 2.0-25.3). Similarly, patients who
received cyclophosphamide as part of their chemotherapy
regimen were at over 2-fold risk (OR 14.8, 95% CI 3.7-59.4)
of developing a second myeloid leukaemia relative to those
patients who received chemotherapy which did not include
cyclophosphamide (OR 6.1, 95% CI 1.5-25.3). Table III
displays the distribution of primary sites of first cancer for
the 22 cases of myeloid leukaemia and controls shown in
Table II treated with chemotherapy that included prednisone,
and the 33 cases of myeloid leukaemia and controls shown in
Table II treated with chemotherapy that included cyclophos-
phamide.
To more completely assess the influence of prednisone on
the risk associated with cyclophosphamide and other drugs
among those without a prior haematologic abnormality,
patients who received chemotherapy were divided into those
who received cyclophosphamide in their protocol and those
who did not. The risk associated with patients who received
chemotherapy that included cyclophosphamide and pred-
nisone (OR 44.4, 95% CI 4.0-496.2) was nearly four times
that associated with patients who received chemotherapy that
included cyclophosphamide, but not prednisone (OR 12.6
95% CI 2.4-64.9) (Table IV). Patients who received drugs
other than cyclophosphamide in their chemotherapy regimen
had a modest but not statistically significant elevated risk of
second myeloid leukaemia (OR 3.2, 95% CI 0.62-16.34) in
the absence of prednisone. However, these patients who
received drugs other than cyclophosphamide in the presence
of prednisone were at substantially higher risk of developing
second myeloid leukaemia (OR 64.2 95% CI 2.6-1582). The
Table I Odds ratios (OR) of second myeloid leukemia following chemotherapy
for a first cancer
Cases Controls OR 95% CIa
All myeloid leukaemia
All subjectsb 30 28 7.8 2.6-22.9
Excluding haematologic abnormality' 30 27 10.3 3.0-34.9
Acute myeloid leukaemia
All subjects 28 26 9.4 2.8-32.3
Excluding haematologic abnormality 28 25 14.0 3.2-60.9
Chronic myeloid leukaemia
All subjects 2 2 2.7 0.2-33.0
Excluding haematologic abnormality 2 2 2.7 0.2-33.0
aCi - Confidence Interval; b97 Cases, 194 Controls; cExcludes 17 matched sets
wherein the case was found to have a haematologic abnormality prior to or at the
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Table II Odds ratios (OR) of second myeloid leukaemia following chemotherapy for a first cancer: Chemotherapy
with and without prednisone and with and without cyclophosphamidea
All myeloid leukaemia Acute myeloid leukemia
Cases Controls OR 95% CIb Cases Controls OR 95% CIb
Prednisone
No chemotherapy (CT) 50 133 1.0 - 33 97 1.0 -
CT without prednisone 17 18 7.1 2.0- 25.3 15 16 9.3 2.1- 42.6
CT with prednisone 13 9 44.8 4.5-443.3 13 9 54.4 4.9-605.5
Cyclophosphamide
No chemotherapy (CT) 50 133 1.0 - 33 97 1.0 -
CT without cyclosphosphamide 10 14 6.1 1.5- 25.3 10 12 9.9 1.9- 51.3
CT with cyclophosphamide 20 13 14.8 3.7- 59.4 18 13 18.1 3.6- 90.8
aExcludes 17 matched sets wherein the case was found to have a haematologic abnormality prior to or at the time
of diagnosis of the first primary cancer; bCI - Confidence Interval.
Table III Site of first primary cancer for cases of second myeloid leukaemia
and controls: Those treated with prednisone and those treated with
cyclophosphamide
Treated with Treated with
prednisone cyclophosphamide
Site offirst primary cancer Cases Controls Cases Controls
Breast 2 2 6 5
Malignant lymphoma 7 7 5 5
Ovary 2 0 5 5
Lung 1 0 3 0
Thyroid 1 0 1 0
Total 13 9 20 13
Table IV Odds ratios (OR) ofsecond myeloid leukaemia following chemotherapy for a first cancer: Chemotherapy
with and without prednisone for those who received and did not receive cyclophosphamidea
All myeloid leukaemia Acute myeloid leukemia
Cases Controls OR 95% CIb Cases Controls OR 95% CIb
No chemotherapy (CT) 50 113 1.0 - 33 97 1.0 -
CT with cyclophosphamide
Without prednisone 11 7 12.6 2.4- 64.9 9 7 12.7 2.1- 77.7
With prednisone 9 6 44.4 4.0-496.2 9 6 51.8 4.4-614.0
CT without cyclophosphamide
Without prednisone 6 11 3.2 0.6- 16.9 6 9 6.2 1.0- 40.1
With prednisone 4 3 64.2 2.6-1582 4 3 75.2 2.9-1947
aExcludes 17 matched sets wherein the case was found to have a haematologic abnormality prior to or at the time
of diagnosis of the first primary cancer; bCI - Confidence Interval.
risks were higher for all drug combinations shown in Table
IV when analyses were restricted to acute myeloid leukaemia.
In order to determine which associations with drugs other
than cyclophosphamide were more likely to be influenced by
simultaneous use with prednisone, risks were calculated for
individual drugs when administered with and without pred-
nisone relative to those not receiving any chemotherapy. The
risk associated with vincristine and 5-fluorouracil were much
higher when these drugs were administered with prednisone
(vincristine: OR 34.6, 95% CI 3.2-373.5; 5-fluorouracil: OR
18.,6, 95% CI 1.1-316) whereas only modest elevations in
risk (within the bounds of chance) were observed due to the
use of these drugs in the absence of prednisone (vincristine:
OR 2.0, 95% CI 0.1-32.0; 5-fluorouracil: OR 2.5, 95% CI
0.5-12.1).
Although no significant increase in risk of second myeloid
leukaemia was associated with the use of drugs known to be
carcinogenic in humans (melphalan) or animals (cisplatin and
adriamycin) when these agents were evaluated individually,
we wished to further evaluate the possibility that the elevated
risk associated with the administration of prednisone could
be accounted for by combined treatment with these agents.
The risk ofmyeloid leukaemia associated with prednisone use
was calculated adjusting for the use of each of these three
drugs individually, and in combination. The risk of second
myeloid leukaemia remained significantly elevated after tak-
ing into account the-use of these agents in all combinations.
No significant independent effects associated with any of
these drugs were found.
Dose of chemotherapy The risks associated with cumulative
and average daily doses of drugs were estimated for all drugs
administered to patients in the study. The risk of second
primary myeloid leukaemia increased with increasing
cumulative doses of prednisone, cyclophosphamide and vin-
cristine. A cumulative dose of cyclophosphamide above
9,000 mg (an approximate cumulative dose in 3 months) was
associated with a higher risk of developing a second myeloid
leukaemia (OR 5.9, 95% CI 1.0-34.2) than cumulative doses
below that level (OR 2.8, 95% CI 0.6-12.6). The relative risk
increased 2-fold when the cumulative dose of cyclophos-
phamide administered was 18,000 mg (about 6 month con-
tinuous therapy) (OR 11.9, 95% CI 2.17-65.04). Prednisone
also showed a significantly elevated odds ratio when patients
received more than 5,000 mg (approximate cumulative dose
in six courses) (OR 5.1, 95% CI 1.1-31.3) compared to those
who received less than 5,000 mg (OR 1.5, 95% CI 0.3-6.4).
Similarly, those who received 10 mg or less of vincristine had
a lower risk of second myeloid leukaemia (OR 3.0, 95% CI
0.4-25.5) compared to those who received more (OR 6.2,
95% CI 0.7- 59.7). A test for trend of increasing cumulative
dose was significant for cyclophosphamide (P = <0.001)
and for prednisone (P = 0.01), but was not significant for
vincristine (P = 0.114).786 A. NANDAKUMAR et al.
An increasing risk with increasing average daily doses of
drug (mg day-') was observed only with cyclophosphamide.
Patients who received more than an average of 37 mg day-'
of cyclophosphamide were at a higher risk of developing
second myeloid leukaemia (OR 21.6, 95% CI 2.80-166.4)
than those who received an average of less than 37 mg day-'
(OR 2.8, 95% CI 0.7-11.7).
Discussion
As in previous studies (Haas et al., 1987; Curtis et al., 1984;
Einhorn, 1978; Boivin et al., 1986; Portugal et al., 1979;
Rosner et al., 1978; Tucker et al., 1987; Reimer et al., 1977;
Kaldor et al., 1990a; Kaldor et al., 1990b) we observed that
chemotherapy for cancer, particularly the administration of
cyclophosphamide, is an important risk factor in the develop-
ment of a subsequent myeloid leukaemia. An elevated risk of
myeloid leukaemia due to radiotherapy was not seen and is
in agreement with previous reports (Boivin & Hutchison,
1981; Valagussa et al., 1986; Kaldor et al., 1990a; Kaldor et
al., 1990b). This investigation has the advantage of being
population-based, and thus is minimally influenced by diag-
nostic staging, or treatment practices, or by patient charac-
teristics or referral patterns which may be peculiar to single
institutions.
The absence of an elevated risk ofmyeloid leukaemia due to
radiotherapy of the first primary is consistent with the analyses
of the risk of second primary leukaemia of any type following
initial primary Hodgkin's disease (Boivin & Hutchison, 1981;
Valagussa et al., 1986; Kaldor et al., 1990a) ovarian cancer
(Mehnert et al., 1986; Kaldor et al., 1990b; Greene et al., 1986)
or breast cancer (Mehnert et al., 1986). As in earlier reports
(Mehnert et al., 1986), a slight but statistically nonsignificant
elevated risk was noted when chronic myeloid leukaemia alone
was considered. A larger sample size would be necessary to
determine more precisely the effect of radiotherapy in the
induction of chronic myeloid leukaemia.
The role of cyclophosphamide as a leukaemogen in acute
myeloid leukaemia is consistent with other reports (Haas et
al., 1987; Portugal et al., 1979; Kaldor et al., 1990a; Kaldor
et al., 1990b; Greene et al., 1986). Further, there was a
suggestion in these data of an increase in risk with increasing
dose of cyclophosphamide. In a previous study (Portugal et
al., 1979) of breast cancer as the first primary, the median
cumulative dose of cyclophosphamide administered was
54,150 mg in 37.5 months. In another report (Greene et al.,
1983), exposed cases with non-Hodgkin's lymphoma who
developed acute nonlymphatic leukaemia received an average
of three times more cyclophosphamide than exposed controls
(71,700 mg in cases vs 23,300 mg in controls). Kaldor et al.
(1990a) report greatly increased risks of acute or non-
lymphocytic leukaemia associated with treatment regimens
for Hodgkin's disease containing cyclophosphamide when
more than six cycles are administered relative to six or fewer
cycles. Similar results are apparent regarding an increase in
risk with increase in cyclophosphamide dose in their com-
parison study of treatment for ovarian cancer (Kaldor et al.,
1990b). Our results suggest that patients receiving higher
doses of cyclophosphamide (intake for more than 5 months
or more than 37 mg per day) are at 10 to 20-fold risk of
myeloid leukaemia compared to those who did not receive
this drug. Due to the relatively small size of this study,
however, the degree to which the risks associated with in-
creasing cumulative months and average daily intake are
independent could not be adequately evaluated in our data.
An unexpected finding of this study is the increased risk of
second primary myeloid leukaemia associated with prior
chemotherapy which included prednisone. Specifically, the
data indicate that the relative risk of second primary myeloid
leukaemia is many times greater when the chemotherapy
administered for an initial primary cancer includeds pred-
nisone than when the chemotherapy regimen does not in-
clude prednisone. It was possible to demonstrate that the risk
of myeloid leukaemia associated with the use of cyclophos-
phamide is enhanced by prednisone. The risk was even
greater when prednisone was administered with chemo-
therapy drugs other than cyclophosphamide. There was no
significantly elevated risk of myeloid leukaemia in patients
who were administered these other drugs (except cyclophos-
phamide) without prednisone. Further analysis of available
data showed that patients administered vincristine and 5-
fluorouracil with prednisone had significantly elevated risk of
second myeloid leukaemia compared to those who received
these drugs without prednisone. It remains to be determined
whether the cell cycle specific action of these drugs (vincris-
tine at mitotic and S phase; 5-fluorouracil at S phase) has
any importance in this context (Carter & Livingston, 1982).
Since no patient received prednisone as a single chemo-
therapy agent, the carcinogenic potential of prednisone alone
could not be assessed.
The apparent action of prednisone could not be explained
on the basis of being administered more often to patients
receiving higher doses of the other chemotherapy agents
(either cumulative or average daily dose), nor could it be
explained on the basis of use in combination with other
drugs known to be carcinogenic in humans (melphalan) or
animals (cisplatin and adriamycin). Similarly, no site or sites
of first primary cancer were associated with a more common
use of prednisone, nor were the uses of radiotherapy and/or
hormone therapy associated with the administration of pred-
nisone.
Reviews regarding the carcinogenicity of prednisone have
been inconclusive due to a paucity of relevant data from
animal and human studies (IARC Monog, 1981). Although
its mechanism of action against the cancer cell is unknown
(Salmon & Sartorelli, 1987), the role of prednisone as a
potential or facilitory carcinogen appears plausible if one
considers the available information regarding some of its
known actions. A primary action of the glucocorticoids (in-
cluding prednisone) appears to be the suppression of
immunologic activities of the host organism. Cells of lym-
phoid origin in culture appear to be more specifically inhibi-
ted by the glucocorticoids than do other cell lines (Calabresi
& Parks, 1985; Wheeler, 1982). Pharmacologic doses of these
steroids produce a profound transient lymphopenia in man
(Beardsley & Cohen, 1978) and, possibly because of this,
prednisone has been particularly effective in bringing early
remission in patients with acute lymphatic leukaemia (Blum
et al., 1982). This implies that the mechanism of action of
prednisone in inducing myeloid leukaemia may be indirect, in
that it possibly interferes with certain natural immunologic
defence mechanisms, perhaps making the myeloid cell more
susceptible or hyperresponsive to other influences such as
alkylating agents or other chemotherapy drugs.
Indirect evidence supporting a role of prednisone in
leukaemogenesis comes from its presence in the MOPP
(Mechlorethamine, Oncovin (vincristine), Prednisone and
Procarbazine) combination chemotherapy regimen commonly
given in treating Hodgkin's disease patients. Treatment with
MOPP has been observed in several studies to be associated
with a high risk of subsequent acute nonlymphatic leukaemia
compared to the alternative regimen ABVD (Adriamycin,
Bleomycin, Vinblastine and Dacarbazine) (Boivin & Hutchi-
son, 1981; Valagussa et al., 1986; Van der Velden et al., 1988;
Valagussa et al., 1982). In a recent report (Van der Velden et
al., 1988), it was observed that all 18 cases of second primary
acute nonlymphatic leukaemia in the study had received
vincristine and procarbazine, while about half of the controls
received that combination. Although cases in that study were
also more likely than controls to have received prednisone in
conjunction with other chemotherapy drugs (89% ofcases vs
52% controls), no analyses were performed to attempt to
delineate any difference in risk between those who received
and did not receive this steroid. Other studies in which all
individual drugs of chemotherapy regimens have been
specified show that most of the patients who developed acute
nonlymphatic leukaemia had been given prednisone as part
of the protocol for treatment of the first primary cancer
(Kushner et al., 1988; Greene et al., 1983). The recentMYELOID LEUKAEMIA FOLLOWING CANCER THERAPY 787
findings of Kaldor et al., (1990a, 1990b) are also generally
consistent with this possibility, although MOPP regimens are
not analysed separately in their study, but rather are included
within a class of treatment characterised by combinations
containing nitrogen mustard and procarbazine.
Findings from Stanford also generally support the present
results, even though prednisone has been omitted from two
cycles of the MOPP treatment regimen for some patients in
their series (Tucker et al., 1988). Whether the risks of subse-
quent leukaemia associated with this modified MOPP therapy
are lower than those reported from other centres which
always include prednisone in MOPP cannot be adequately
evaluated from the published literature.
The single unique finding of this study is the possible role
of prednisone as a co-carcinogen in enhancing the leukae-
mogenic action of other chemotherapy drugs. Although this
investigation constitutes the largest sample yet reported for a
specific type of leukaemia, a larger number ofcases is needed
to better evaluate the etiologic role of individual
chemotherapeutic agents, particularly in combination with
prednisone. Thus, the present results call for more rigorous
evaluation of the role of this commonly used steroid in the
etiology of leukaemia. In conducting further investigations of
second primary leukaemias it will be important to evaluate
the use of prednisone in combination chemotherapy, and to
consider its intake for other ailments. Research at the experi-
mental and molecular levels may also provide clues regarding
drug interaction and carcinogenesis. Detailed information on
past and present history of prednisone administration for
associated nonmalignant conditions will be of importance in
assessing its potential carcinogenic activity.
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